Santa Clara, California, July 21, 2014
Nanosyn, Inc. announced today a multi-year research services agreement with FORMA Therapeutics, Inc., to provide access to Nanosyn's microfluidics screening and profiling capabilities and proprietary fragment-based lead discovery platform for novel small molecule therapeutics.
"We are really excited about the opportunity to work with FORMA Therapeutics to explore key pathways in the fields of epigenetics and protein homeostasis. FORMA Therapeutics' decision to work with us is further recognition of our track record in advancing compounds into clinic," said Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc. "We are pleased to work with such a world class company and very much look forward to a productive partnership."
"At FORMA, we come to work every day with the goal of finding new cures for cancer and other devastating diseases by focusing on unmet medical needs," stated Kenneth W. Bair, Ph.D., Chief Scientific Officer and Head of Research and Development, FORMA Therapeutics, Inc. "This expanded collaboration with Nanosyn will accelerate the creation and evaluation of new molecules, hopefully resulting in breakthrough medicines for patients."
The agreement provides FORMA the opportunity to access Nanosyn's unique expertise, which ranks as one of the largest industry providers of lab-on-a-chip biology services with over 500 high precision mobility-shift assays already developed by the Nanosyn discovery biology and medicinal chemistry teams.
The services will include:
- Access to Nanosyn's microfluidics screening and profiling services, as well as proprietary fragment-based screening drug discovery platform.
- Development of panels of novel assays to support FORMA's epigenetic and protein homeostasis programs, including screening against both FORMA's and Nanosyn's proprietary chemical libraries.
- FORMA to support biology and medicinal chemistry activities at Nanosyn for FORMA's hit-to-lead and lead optimization programs.
Nanosyn, Inc. is a Contract Research Organization providing integrated drug discovery and development services, medicinal chemistry, made-to-order focused compound libraries, lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA.